Free Trial

Physiomics (PYC) Competitors

Physiomics logo
GBX 0.47 +0.02 (+4.00%)
As of 06/13/2025 09:54 AM Eastern

PYC vs. EVG, MTFB, GENF, DEST, BSFA, ROQ, RENE, VAL, SALV, and TCF

Should you be buying Physiomics stock or one of its competitors? The main competitors of Physiomics include Evgen Pharma (EVG), Motif Bio (MTFB), Genflow Biosciences (GENF), Destiny Pharma (DEST), BSF Enterprise (BSFA), Roquefort Therapeutics (ROQ), ReNeuron Group (RENE), ValiRx (VAL), SalvaRx Group (SALV), and Theracryf (TCF). These companies are all part of the "biotechnology" industry.

Physiomics vs. Its Competitors

Physiomics (LON:PYC) and Evgen Pharma (LON:EVG) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, earnings, profitability, analyst recommendations, dividends, valuation, risk and community ranking.

Evgen Pharma has a net margin of 0.00% compared to Physiomics' net margin of -106.80%. Evgen Pharma's return on equity of -60.57% beat Physiomics' return on equity.

Company Net Margins Return on Equity Return on Assets
Physiomics-106.80% -127.68% -76.38%
Evgen Pharma N/A -60.57%-45.52%

Physiomics has a beta of 1.69, suggesting that its share price is 69% more volatile than the S&P 500. Comparatively, Evgen Pharma has a beta of 1.44, suggesting that its share price is 44% more volatile than the S&P 500.

In the previous week, Physiomics' average media sentiment score of 0.00 equaled Evgen Pharma'saverage media sentiment score.

Company Overall Sentiment
Physiomics Neutral
Evgen Pharma Neutral

Physiomics has higher revenue and earnings than Evgen Pharma. Physiomics is trading at a lower price-to-earnings ratio than Evgen Pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Physiomics£864.07K1.11-£922.82K-£0.45-1.05
Evgen PharmaN/AN/A-£3.35M-£0.01N/A

27.8% of Evgen Pharma shares are held by institutional investors. 4.2% of Physiomics shares are held by insiders. Comparatively, 32.4% of Evgen Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Evgen Pharma received 113 more outperform votes than Physiomics when rated by MarketBeat users. Likewise, 74.23% of users gave Evgen Pharma an outperform vote while only 55.56% of users gave Physiomics an outperform vote.

CompanyUnderperformOutperform
PhysiomicsOutperform Votes
80
55.56%
Underperform Votes
64
44.44%
Evgen PharmaOutperform Votes
193
74.23%
Underperform Votes
67
25.77%

Summary

Evgen Pharma beats Physiomics on 8 of the 12 factors compared between the two stocks.

Get Physiomics News Delivered to You Automatically

Sign up to receive the latest news and ratings for PYC and its competitors with MarketBeat's FREE daily newsletter.

PYC vs. The Competition

MetricPhysiomicsBiotechnology IndustryMedical SectorLON Exchange
Market Cap£960K£124.82M£5.57B£2.91B
Dividend Yield6.20%3.74%5.28%4.90%
P/E Ratio-1.053.2526.75124.60
Price / Sales1.114,108.15408.11248,064.90
Price / Cash4.2113.1938.2528.07
Price / Book2.2435.866.964.64
Net Income-£922.82K-£91.56M£3.23B£5.91B
7 Day Performance1.74%0.34%-1.19%12.86%
1 Month Performance12.50%6.24%8.50%25.97%
1 Year Performance-66.57%180.82%33.53%77.95%

Physiomics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PYC
Physiomics
N/AGBX 0.47
+4.0%
N/A-62.4%£960K£864.07K-1.0510Gap Up
EVG
Evgen Pharma
N/AN/AN/AN/A£3.42MN/A-80.0010
MTFB
Motif Bio
N/AN/AN/AN/A£3.28MN/A-0.036
GENF
Genflow Biosciences
N/AGBX 0.88
+3.5%
N/A-74.1%£3M-£226.19K-1.665Gap Down
DEST
Destiny Pharma
N/AN/AN/AN/A£2.87M£135.03K-50.0024Gap Down
High Trading Volume
BSFA
BSF Enterprise
N/AGBX 2.13
-10.3%
N/A-59.9%£2.63M£80.25K-1.2912Gap Up
ROQ
Roquefort Therapeutics
N/AGBX 1.64
-8.9%
N/A-66.7%£2.09M£2.66K-1.359Gap Down
RENE
ReNeuron Group
N/AN/AN/AN/A£1.93M£783K-37.502Gap Down
VAL
ValiRx
N/AGBX 0.50
+4.8%
N/A-82.2%£1.89M£27.78K-0.345,450Earnings Report
Gap Up
SALV
SalvaRx Group
N/AN/AN/AN/A£1.65M£64.50M0.032Gap Up
TCF
Theracryf
N/AGBX 0.28
+5.7%
N/A-76.6%£1.34M£687.67K-0.2710Gap Up

Related Companies and Tools


This page (LON:PYC) was last updated on 6/14/2025 by MarketBeat.com Staff
From Our Partners